Merit Medical to Acquire Needle Biopsy Products in Purchase Agreement With BD
November 21, 2017—Merit Medical Systems, Inc. announced that it has signed an asset purchase agreement to acquire with BD’s (Becton, Dickinson and Company) soft tissue core needle biopsy products, which include the Achieve programmable automatic biopsy system, Temno biopsy system, and Tru-Cut biopsy needles. This agreement is in connection with and subject to closing of BD’s proposed acquisition of C.R. Bard, Inc. and other customary closing conditions.
In addition, Merit proposes to acquire Bard’s Aspira pleural effusion drainage kits and Aspira peritoneal drainage system.
The current purchase price for these product lines and related assets is $100 million, advised the company in its announcement.